Expanding horizons in complement drug discovery: challenges and emerging strategies
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The complement system is best known for its role in innate immunity, providing a first line of defence against infection, maintaining tissue homeostasis by flagging apoptotic cells and debris for removal, and orchestrating crosstalk between adaptive and innate immunity. In a growing number of diseases, complement is known to drive pathogenesis or to contribute as an inflammatory amplifier of a disease trigger. Association of complement with common and devastating diseases has driven an upsurge in complement drug discovery, but despite a wealth of knowledge in the complexities of the cascade, and many decades of effort, very few drugs have progressed to late-stage clinical studies. The reasons for this are becoming clear with difficulties including high target concentration and turnover, lack of clarity around disease mechanism and unwanted side effects. Lessons learnt from drugs which are either approved, or are currently in late-stage development, or have failed and dropped off the drug development landscape, have been invaluable to drive a new generation of innovative drugs which are progressing through clinical development. In this review, the challenges associated with complement drug discovery are discussed and the current drug development landscape is reviewed. The latest approaches to improve drug characteristics are explored and those agents which employ these technologies to improve accessibility to patients are highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Complement and its role in innate and adaptive immune responses
Dunkelberger, J. R., & Song, W.-C. (2010) · Cell Research · doi:10.1038/cr.2009.139 · Cited by 1,932 · cited 1×
“In health, the system is constantly activating, but that is in perfect balance with control mechanisms which allow sufficient flux through the pathway to recognise appropriate (foreign) targets, but limit ‘tickover’ amplification and activation on self-surfaces [3, 9].”
BackgroundGene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184 · cited 1×
“There remains untapped potential for modulating complement at the genetic level using cell- or gene-targeting strategies [80, 81].”
BackgroundThe complement system in regulation of adaptive immunity
Carroll, M. C. (2004) · Nature Immunology · doi:10.1038/ni1113 · Cited by 1,035 · cited 1×
“Opsonisation of antigens with the complement fragment, C3dg, results in coengagement of the B cell receptor and complement receptor 2 (CR2; CD21) and synergistic downstream signalling, lowering the threshold concentration of antigen required to activate the cell [5, 6].”
BackgroundRother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778 · cited 1×
“Eculizumab prevents the proinflammatory impacts of C5a and MAC evident in aHUS, and prevents the MAC from lysing and activating cells in PNH; thus, blockade at the level of C5 can relieve symptoms [42].”
BackgroundComplement and Its Receptors: New Insights into Human Disease
Holers, V. M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120154 · Cited by 430
Cited by
Single-Cell RNA Sequencing Reveals a Dynamic Stromal Niche That Supports Tumor Growth
Davidson, S., Efremova, M., Riedel, A., Mahata, B., Pramanik, J., Huuhtanen, J., Kar, G., Vento-Tormo, R., Hagai, T., Chen, X., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107628 · Cited by 323
The good, the bad, and the opportunities of the complement system in neurodegenerative disease
Schartz, N. D., & Tenner, A. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02024-8 · Cited by 286
Mongan, D., Ramesar, M., Föcking, M., Cannon, M., & Cotter, D. (2020) · Early Intervention in Psychiatry · doi:10.1111/eip.12859 · Cited by 123
“Challenges in the development of drugs targeting the complement system include potential side-effects such as increased risk of infection (Harris, 2017) and, importantly for psychiatric disorders, ensuring enough drug reaches and remains active within the brain (Morgan, 2017).”
BackgroundDiseases of complement dysregulation-an overview
Wong, E. K. S., & Kavanagh, D. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0663-8 · Cited by 115
Hammadi, S., Tzoumas, N., Ferrara, M., Meschede, I. P., Lo, K., Harris, C., Lako, M., & Steel, D. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082870 · Cited by 44
“Homing agents that bind to neoepitopes on complement proteins or stress-related antigens on apoptotic or necrotic cells may offer an additional way of restricting drug action to inflammation hotspots and reducing the risk of widespread systemic effects [225], though it is unclear how such a therapy would specifically…”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Harris, C. L.
- Venue
- Seminars in Immunopathology
- Published
- 2017-10-06
- Volume
- 40
- Issue
- 1
- Pages
- 125-140
- ISSN
- 1863-2297 (ISSN-L)
- 1863-2300
- OpenAlex
- W2762413777
- Cited by
- 63
- References
- 6
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.